Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Arthritis Rheum ; 44(7): 1568-81, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11465708

ABSTRACT

OBJECTIVE: To examine the expression of the novel CX3C chemokine fractalkine (Fkn) and its receptor (CX3CR1) in rheumatoid arthritis (RA) and rat adjuvant-induced arthritis (AIA), a model of RA. METHODS: Immunohistochemistry, flow cytometry, enzyme-linked immunosorbent assay (ELISA), reverse transcriptase-polymerase chain reaction (RT-PCR), and chemotaxis assays were used. RESULTS: In rat AIA, synovial tissue (ST) macrophages, fibroblasts, endothelial cells, and dendritic cells were Fkn immunopositive, whereas lymphocytes did not significantly express Fkn. Significant staining for CX3CR1 was found in ST macrophages, fibroblasts, and dendritic cells, whereas only a small percentage of endothelial cells stained for CX3CR1 in rat AIA. We immunolocalized Fkn to RA ST macrophages, fibroblasts, endothelial cells, and dendritic cells. We also found intense ST macrophage and dendritic cell staining for CX3CR1 in RA ST. Flow cytometry analysis of RA synovial fluid (SF) and peripheral blood revealed a greater percentage of monocytes expressing Fkn and CX3CR1 compared with T cells. By ELISA, we found significantly elevated soluble Fkn (sFkn) levels in RA SF compared with SF from patients with osteoarthritis or other forms of arthritis. By RT-PCR, we found enhanced expression of Fkn and CX3CR1 mRNA on day 18 in rat AIA, a time of pronounced inflammation in the rat joint. Soluble Fkn-depleted RA SF showed significantly decreased chemotactic activity for monocytes compared with sham-depleted RA SF. CONCLUSION: These results indicate that Fkn and its receptor are both expressed in RA and in rat AIA, and that sFkn is up-regulated in RA SF. Furthermore, our data suggest a new role for Fkn in monocyte chemotaxis in the inflamed RA joint.


Subject(s)
Arthritis, Experimental/metabolism , Arthritis, Rheumatoid/metabolism , Chemokines, CX3C/genetics , Membrane Proteins/genetics , Receptors, Cytokine/genetics , Receptors, HIV/genetics , Adult , Animals , Arthritis, Experimental/immunology , Arthritis, Rheumatoid/immunology , CD3 Complex/analysis , CX3C Chemokine Receptor 1 , Chemokine CX3CL1 , Chemokines, CX3C/analysis , Chemotaxis, Leukocyte/immunology , Enzyme-Linked Immunosorbent Assay , Female , Fibroblasts/drug effects , Fibroblasts/metabolism , Flow Cytometry , Gene Expression/immunology , Humans , Interleukin-1/pharmacology , Kinetics , Lipopolysaccharide Receptors/analysis , Membrane Proteins/analysis , Monocytes/chemistry , Monocytes/cytology , Monocytes/immunology , RNA, Messenger/analysis , Rats , Rats, Inbred Lew , Receptors, Cytokine/analysis , Receptors, HIV/analysis , Solubility , Synovial Fluid/immunology , Synovial Fluid/metabolism , T-Lymphocytes/chemistry , T-Lymphocytes/immunology , Tarsus, Animal/immunology , Tarsus, Animal/metabolism , Tumor Necrosis Factor-alpha/pharmacology , Up-Regulation/immunology
2.
Arthritis Rheum ; 44(1): 31-40, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11212173

ABSTRACT

OBJECTIVE: Angiogenesis, the growth of new blood vessels, is vital to the ingress of inflammatory leukocytes in rheumatoid arthritis (RA) synovial tissue and to the growth and proliferation of RA pannus. The factors that mediate the growth of new blood vessels have not been completely defined. This study examined the ability of Glu-Leu-Arg (ELR)-containing chemokines to induce angiogenesis in the RA joint. METHODS: To reflect angiogenic activity in vivo, we selected a model using whole human synovial tissue rather than isolated cells. Tissues were examined by immunohistochemistry and enzyme-linked immunosorbent assay, and tissue homogenates were immunoneutralized and assayed for their ability to induce endothelial cell chemotaxis and rat corneal neovascularization. RESULTS: Cells expressing interleukin-8 (IL-8) and epithelial neutrophil activating peptide 78 (ENA-78) were located in proximity to factor VIII-related antigen-immunopositive endothelial cells. RA homogenates produced more IL-8 and ENA-78 compared with normal synovial tissue homogenates. Moreover, homogenates from RA synovial tissue produced significantly more chemotactic activity for endothelial cells in vitro and angiogenic activity in the rat cornea in vivo than did normal synovial tissue homogenates. The effects of IL-8 and ENA-78 accounted for a significant proportion of the chemotactic activity of endothelial cells and angiogenic activity found in RA synovial tissue homogenates. CONCLUSION: These results indicate that the ELR-containing chemokines IL-8 and ENA-78 are important contributors to the angiogenic activity found in the inflamed RA joint. It is possible that efforts aimed at down-regulating these chemokines offer a novel targeted therapy for the treatment of RA.


Subject(s)
Arthritis, Rheumatoid/physiopathology , Chemokines, CXC/pharmacology , Interleukin-8/analogs & derivatives , Interleukin-8/pharmacology , Neovascularization, Pathologic/drug therapy , Adult , Aged , Aged, 80 and over , Animals , Arthroplasty , Chemokine CXCL5 , Chemotaxis, Leukocyte/drug effects , Chemotaxis, Leukocyte/immunology , Endothelium, Vascular/cytology , Endothelium, Vascular/immunology , Female , Humans , Male , Middle Aged , Neutrophil Activation/drug effects , Neutrophil Activation/immunology , Synovial Membrane/drug effects
3.
J Immunol ; 166(2): 1214-22, 2001 Jan 15.
Article in English | MEDLINE | ID: mdl-11145704

ABSTRACT

IL-4 is a cytokine with anti-inflammatory properties on activated macrophages. Rheumatoid arthritis, an autoimmune inflammatory disease, is characterized by a paucity of IL-4 and an abundance of synovial macrophage-derived mediators. Herein, the effect of a single injection of adenovirus-producing rat IL-4 (AxCAIL-4) or a control virus with no inserted gene was compared with the effect of PBS injection into rat ankles. Ankles were injected before arthritis onset or at maximal inflammation. Preventatively, AxCAIL-4 reduced adjuvant-induced arthritis (AIA)- and/or AIA/adenoviral-induced ankle inflammation, decreasing articular index scores, ankle circumferences, paw volumes, radiographic scores, mean levels of monocyte chemoattractant protein-1, the number of inflammatory cells, and the number of synovial blood vessels. Therapeutically, AxCAIL-4 also decreased ankle circumferences and paw volumes in comparison with a control virus with no inserted gene and PBS groups. After arthritis onset, mean levels of TNF-alpha, IL-1beta, macrophage inflammatory protein-2, and RANTES were decreased in AxCAIL-4 rat ankle homogenates compared with PBS-treated homogenates. Thus, increased expression of IL-4 via gene therapy administered in a preventative and/or therapeutic manner reduced joint inflammation, synovial cellularity, levels of proinflammatory cytokines, vascularization, and bony destruction in rat AIA, suggesting that a similar treatment in humans may be beneficial.


Subject(s)
Adenoviruses, Human/genetics , Arthritis, Experimental/prevention & control , Bone Resorption/prevention & control , Cytokines/antagonists & inhibitors , Genetic Therapy , Inflammation Mediators/antagonists & inhibitors , Interleukin-4/genetics , Neovascularization, Pathologic/prevention & control , Adenoviruses, Human/immunology , Animals , Arthritis, Experimental/immunology , Arthritis, Experimental/pathology , Arthritis, Experimental/physiopathology , Bone Resorption/immunology , Bone Resorption/pathology , Bone Resorption/physiopathology , Chickens , Dose-Response Relationship, Immunologic , Female , Genetic Therapy/methods , Genetic Vectors/administration & dosage , Genetic Vectors/immunology , Hindlimb , Humans , Injections, Intra-Articular , Interleukin-4/biosynthesis , Mutagenesis, Insertional/methods , Neovascularization, Pathologic/immunology , Neovascularization, Pathologic/pathology , Neovascularization, Pathologic/physiopathology , Rats , Rats, Inbred Lew , Viral Plaque Assay/methods
4.
Parasite Immunol ; 22(8): 373-80, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10972844

ABSTRACT

Antibodies raised against an Escherichia coli-produced recombinant protein encoding a 76-kDa section (region C) of malaria transmission-blocking vaccine candidate, Pfs230, have previously been shown to significantly reduce the ability of Plasmodium falciparum parasites to infect mosquitoes (71.2-89.8%). To further define the region of the Pfs230 required for transmission-blocking activity, four recombinant proteins each encoding a section of region C (Pfs230 amino acids 443-1132) were produced using the same E. coli expression system and tested for immunogenicity in mice: (i) r230/MBP.C5' encodes the first half of region C (amino acids 443-791, six cysteines); (ii) r230/MBP.CM1 encodes only cysteine motif (CM) 1 (amino acids 583-913, eight cysteines); (iii) r230/MBP.C1.6 (amino acids 453-913, eight cysteines) also includes all of CM1; and (iv) r230/MBP.C2 encodes only CM2 (amino acids 914-1268, 11 cysteines). All the recombinant proteins induced antibodies that recognized parasite-produced Pfs230, but the titre of the Pfs230 specific-antibodies generated varied, C = C1.6 = C5' > CM1 > CM2. Two recombinants, r230/MBP.C5' and r230/MBP.C1.6, induced antibody titres that were equivalent to or greater than the titre generated by r230/MBP.C. However, in contrast to r230/MBP.C, none of the recombinants induced antibodies that effectively blocked parasite infectivity to mosquitoes. This suggests that the inclusion of amino acids 914-1132 is important for the production of the transmission-blocking epitope present in region C.


Subject(s)
Anopheles/parasitology , Antibodies, Protozoan/biosynthesis , Malaria Vaccines/immunology , Malaria, Falciparum/transmission , Plasmodium falciparum/immunology , Protozoan Proteins/immunology , Animals , Antibodies, Protozoan/blood , Antibodies, Protozoan/immunology , Antigens, Protozoan/immunology , Enzyme-Linked Immunosorbent Assay/methods , Fluorescent Antibody Technique, Indirect , Humans , Immunoblotting , Malaria, Falciparum/immunology , Mice , Plasmodium falciparum/growth & development , Protozoan Proteins/genetics , Recombinant Fusion Proteins/immunology , Vaccination , Vaccines, Synthetic/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...